摘要
目的探讨乳腺癌不同分子分型与新辅助化疗前后GST-π和Topo-Ⅱ表达的相关性。方法对155例乳腺癌患者进行分子分型,采用免疫组织化学En Vison二步法检测不同分型患者GST-π和Topo-Ⅱ表达情况,并结合病理特点进行分析。结果 HER2过表达型及Basal-like型GST-π表达率高于Luminal A型和Luminal B型(P均<0.05)。HER2过表达型及Basal-like型Topo-Ⅱ表达率低于Luminal A型和Luminal B型,但差异无统计学意义(P均>0.05)。不同分型患者GST-π表达情况与患者新辅助化疗疗效之间无明显相关性(P>0.05),不同分型患者Topo-Ⅱ表达情况与新辅助化疗疗效有关(P<0.05)。结论乳腺癌中GST-π的表达情况与化疗药物作用无明显相关性,而Topo-Ⅱ表达量的高低与化疗药物作用成正相关性,Topo-Ⅱ的表达有助于判断乳腺癌的预后及为用药提供选择依据。
Objective It is to investigate the correlation of breast cancer molecular classification with the expression of GST -πand Topo - Ⅱ before and after neoadjuvant chemotherapy. Methods 155 patients with breast cancer were selected to carry on the molecular classification, the expression of GST - π and Topo - Ⅱwere detected by using immunohistochemical de- tection EnVison ldpe - g - nvp in patients with different parting, and the data were analyzed combining the pathological fea- tures. Results The expression of GST - π in HER2 expression type and Basal-like type was higher than LuminalA and Lumi- nalB type （ all P 〈 0.05 ）. The expression of Topo - Ⅱ in HER2 expression type and Basal-like type was lower than LuminalA and LuminalB type, but there was no significant difference （ all P 〉 0.05 ）. There was no significant correlation between the expression of GST - π in patients with different parting and neoadjuvant chemotherapy curative effect （ P 〉 0.05 ） , but the To- po- Ⅱ expression in different classification was related to the curative effect of neoadjuvant chemotherapy in patients with difference parting （ P 〈 0.05）. Conclusion The expression of GST -π in breast cancer has no significant correlation with neo- adjuvant chemotherapy curative effect, but the Topo - Ⅱ expression in different classification is related to the curative effect of neoadjuvant chemotherapy in patients with difference parting. The expression of Topo - Ⅱ can help to judge the prognosis of breast cancer and provide basis for the selection of drug.
出处
《现代中西医结合杂志》
CAS
2015年第24期2643-2645,2651,共4页
Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词
乳腺癌
分子分型
新辅助化疗
免疫组化
breast cancer
molecular classification
neoadjuvant chemotherapy
immunohistochemical
